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Abstract
Background: Cervical cerclage is a surgical procedure involving suturing the cervix with a purse
type stitch to keep it closed during pregnancy. This procedure has been used widely in the
management of pregnancies considered at high risk of preterm delivery. Several observational
studies into the efficacy of cervical cerclage have claimed high rates of successful pregnancy
outcome in women with a poor obstetric history attributed to cervical incompetence. However, a
recent aggregate data Cochrane review found no such conclusive evidence from seven included
randomised studies. Current data suggests that cervical cerclage is likely to benefit women
considered to be 'at very high risk' of a second trimester miscarriage due to a cervical factor,
however identifying such women remains elusive and many women may be treated unnecessarily.
Undertaking an individual patient data (IPD) meta-analysis of the studies will allow us to investigate
whether treatment is more effective in particular subgroups. Such an analysis will also provide a
more powerful analysis of the predictors of preterm delivery and pregnancy loss, including
ultrasound measurement of cervical length, and will allow a more complete analysis of 'time to
event' outcomes.
Methods/Design: The analysis will include data from randomised trials comparing the
intervention of elective cerclage versus no cerclage or bedrest to prevent miscarriage or pre-term
labour. A specific list of data will be requested for each trial, including demographic and obstetric
history data. The primary outcomes of interest will be neonatal mortality/morbidity. Attention will
also be given to secondary outcomes such as time from randomisation to delivery, preterm delivery
before 32 weeks and maternal morbidity. An intention to treat analysis will be performed, with
attention paid to assessing clinical and statistical heterogeneity. Multilevel models with patients and
trials as the two levels will be explored to investigate treatment effect on various outcomes.
Patient-level covariates will be incorporated into the models in an attempt to account for statistical
heterogeneity as well as to investigate interactions with treatment effect.
Discussion: Predictive models generated from our analysis should lead to more effective
counselling of women at risk and a more cost effective use of cerclage.
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Cervical cerclage is a surgical procedure carried out during
pregnancy. The operation involves suturing the neck of
the womb (cervix) with a purse type stitch to keep the cer-
vix closed. This surgical procedure has been used widely in
the management of pregnancies considered to be at high
risk of preterm delivery.
Several observational studies in the last 50 years have
claimed high rates of successful pregnancy outcome in
women that had a poor obstetric history attributed to cer-
vical incompetence. However, a recent Cochrane review
found no conclusive evidence from seven included ran-
domised studies that inserting a cervical stitch in women
perceived to be at risk of preterm birth or second trimester
pregnancy loss attributed to cervical factors, reduces the
risk of pregnancy loss, preterm delivery or morbidity asso-
ciated with preterm delivery (Drakeley 2003)[1].
In the Cochrane review, the data for important clinical
outcomes including preterm delivery and maternal infec-
tion showed significant heterogeneity due to inconsist-
ency in clinical definitions used, including the cut off
gestational age defining preterm delivery, and different
patient populations studied.
Practically, methods of undertaking a meta-analysis of
several studies may involve collecting either aggregate
data, or data on each patient individually. The advantages
of the latter approach, described as the 'yardstick' (Chalm-
ers 1993)[2] include (i) a more complete analysis of 'time
of event' outcomes and (ii) a more powerful analysis of
whether treatment is more or less effective in particular
subgroups (Stewart 1993)[3].
One of the main concerns regarding current evidence
related to cervical cerclage and other interventions for pre-
ventions of preterm delivery is a possibility that the 'pri-
mary outcomes' may have been selected to give results in
greatest accord with the a priori beliefs of the authors. The
evidence to support this phenomenon of within-study
selective reporting comes from empirical research, which
demonstrates discrepancies between research protocols
and subsequent publications (Hahn 2002 [4], William-
son 2005 [5], Chan 2004 [6]). Individual patient data
(IPD) meta-analysis has the capacity to overcome these
problems.
Currently available data suggest that cervical cerclage is
likely to be of benefit for women considered 'at very high
risk' of second trimester miscarriage due to a cervical fac-
tor e.g. greater than two second trimester losses or progres-
sive shortening of the cervix on ultrasound. However,
predicting those women who will miscarry due to a cervi-
cal factor remains elusive and many women may be
treated unnecessarily. The use of IPD will allow us to
investigate predictors of preterm delivery including ultra-
sound measurement of cervical length and other woman-
cerclage interactions.
IPD meta-analysis will allow an investigation of the
hypothesis that the effect of cerclage is greater on extreme
preterm delivery. In addition, an IPD meta-analysis has
greater power than a single trial for examining subgroups.
The efficacy of a treatment may depend on several factors.
For aggregate data, a meta-analysis stratifying by the abso-
lute risk in the control group may be the only method pos-
sible for accounting for these multiple factors
simultaneously. This analysis is 'flawed and produces seri-
ously misleading results' (Sharp 1996)[7]. A regression
analysis of IPD allows the relation between treatment
effect and risk score, derived from these multiple risk fac-
tors, to be investigated thereby avoiding these problems.
Methods/Design
Objectives
The aim of this project is to undertake an IPD meta-anal-
ysis of randomised trials of cervical cerclage. Specific
objectives are as follows.
1. To estimate the effect of cervical cerclage on gestational
age at delivery.
2. To investigate whether cervical cerclage is more likely to
prevent extreme prematurity (<28 weeks) or delivery at
later gestations.
3. To investigate risk factors for preterm delivery.
4. To investigate interactions between risk factors and cer-
vical cerclage.
5. To model the effect of cervical cerclage and other risk
factors on neonatal and maternal morbidity.
Criteria for considering studies for this IPD meta-analysis
The types of studies considered for inclusion in the analy-
sis will be all randomised trials comparing cervical cer-
clage with expectant management or no cerclage during
pregnancy. The previous Cochrane review (Drakeley
2003) [1] identified eight eligible trials with 2,513 ran-
domised women (Rust 2000 [8], Althuisius 2000 [9],
Althuisius 2001 [10], Rush 1983 [11], Lazar 1984 [12],
Dor 1982 [13], MRC/RCOG 1988 [14], Meekai To et al.
[15]). We have agreement in principle to provide IPD
from six of these trials (Meekai To et al. [15], MRC/RCOG
1988 [14], Rust 2000 [8], Althuisius 2000 [9], Althuisius
2001 [10], Rush 1983 [11]), accounting for 1919(78%) of
all women randomised. The remaining trialists and trial-
ists of any further trials identified as eligible will bePage 2 of 5
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their willingness to collaborate. Already, two further trials
have been identified (Berghella 2004 [16], Ezechi 2003
[17]) and the authors have agreed to provide IPD from
these trials.
The data collected in the studies will relate to women with
confirmed, or suspected of having, cervical incompetence
who desire future pregnancies and women who present as
an emergency and are thought to have a diagnosis of cer-
vical incompetence. The intervention investigated in the
studies will be elective cerclage by whichever method
(Shirodkar technique, McDonald technique, transabdom-
inal and transvaginal methods), versus no cerclage or bed
rest as interventions to prevent miscarriage or pre-term
labour as defined in the original Cochrane review (Drake-
ley 2003)[1].
Search strategy for identification of studies
The methods of trial identification described in the origi-
nal Cochrane review (Drakeley 2003)[1] (see below) will
be adopted and updated to December 2004.
The original review has drawn on the search strategy
developed for the Pregnancy and Childbirth Group. The
full list of journals and conference proceedings as well as
the search strategies for the electronic databases, which are
searched by the Group on behalf of its reviewers, are
described in detail in the 'Search strategies for the identi-
fication of studies section' within the editorial informa-
tion about the Cochrane Pregnancy and Childbirth
Group. Briefly, the Trials Search Coordinator searches on
a regular basis MEDLINE, the Cochrane Controlled Trials
Register and reviews the Contents tables of a further 38
relevant journals received via ZETOC, an electronic cur-
rent awareness service.
In addition, handsearches will be performed on congress
proceedings of the International and European society
meetings of feto-maternal medicine, recurrent miscarriage
and reproductive medicine. Whenever possible, investiga-
tors will be contacted to ask about any additional studies
potentially eligible for inclusion.
Trial eligibility and methodological quality assessment
Two reviewers will independently assess eligibility of
identified randomised controlled trials for inclusion in
the review. Any difference of opinion will be resolved by
discussion. The methodological quality of each trial will
be assessed by summarising the method of generation of
randomisation list, method of allocation concealment,
and potential impact of losses to follow-up. Quasi-ran-
domised studies in which allocation was transparent (e.g.
use of alternative allocation or medical record numbers)
were excluded in the original review.
Data collection
The following data for each woman/infant pair will be
requested from all trials: date of randomisation and gesta-
tional age, maternal demographics and obstetric charac-
teristics at randomisation including cervical length on
ultrasound, fibronectin and bacterial vaginosis data if
available, treatment allocated, complications during preg-
nancy including ruptured membranes, maternal pyrexia
or chorioamnionitis, date of delivery, gestational age at
delivery and all neonatal data including birthweight,
length of stay at NICU and morbidity related to prematu-
rity.
The following methodological data will also be requested
for all trials: method of generation of randomisation list,
method of concealment of randomisation, stratification
factors and blinding methods.
Data will be accepted either in electronic (floppy disk/
CD/internet) or paper form. A desired format and coding
will be specified but trialists may supply data in the most
convenient way open to them, providing details of coding
are sent with the data.
Data validation strategy
A copy of the original data sent (before checking) will be
held in a separate file. The following procedures will then
be performed and documented for all trial data supplied.
Trial details will be crosschecked against any published
report of the trial. Range and consistency checks will be
applied – missing data, errors and inconsistencies will be
followed up with a nominated individual. The chronolog-
ical randomisation sequence will be reviewed. The bal-
ance of prognostic factors will be checked, taking into
account of factors stratified for in the randomisation pro-
cedure.
Outcome measures
The primary outcome of interest will be neonatal mortal-
ity/morbidity. Choice of primary outcome is about what
should determine clinical decision-making. However it is
recognised that trials to date may have insufficient power
and there is a need to consider secondary outcomes of
time from randomisation to delivery, preterm delivery
before 32 completed weeks (<32+0 weeks) and maternal
morbidity as defined in the Cochrane Review (Drakeley
2003)[1]. We will aim to obtain all neonatal and maternal
morbidity outcome data collected in each trial and not
just those reported in publications.
Reporting of these outcomes in the original trial report is
not an eligibility requirement for this review.Page 3 of 5
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Data on all randomised patients will be requested to per-
form an intention-to-treat analysis as far as possible. Clin-
ical heterogeneity will be assessed by reviewing the
differences across trials in characteristics of randomised
patients.
Initially, an aggregate data analysis will be undertaken
although treatment effect estimates will be obtained from
the individual patient data. Binary outcomes will be sum-
marised in terms of odds ratios or relative risks, depend-
ing on the degree of heterogeneity observed. Time-to-
event outcomes will be summarised in terms of the log
(hazard ratio). The I square statistic and chi-square test for
statistical heterogeneity will be applied to these summary
data.
Regression models, stratified by trial, will be used to
explore the effects of treatment, risk factors and treatment-
covariate interactions on the various outcomes of interest.
These will include Cox and accelerated life models for
time-to-event outcomes (Tudur-Smith 2004 [18], Wil-
liamson 2002 [19]) and logistic regression models with
trial indicator variables for binary outcomes (Whitehead
2002) [20]. Factors other than treatment to be investi-
gated are gestational age at randomisation, maternal
demographics, obstetric characteristics including obstetric
history, cervical length on ultrasound, fibronectin, bacte-
rial vaginosis, multiple pregnancy.
Two-level multilevel regression models will be fitted with
patients corresponding to level one units and trials as level
two units for the various outcomes of interest, adopting
the relevant approach for continuous, binary, categorical
and time to event outcomes as applicable. Trial effects will
be represented by fixed effects whilst treatment effects will
be represented by random effects in an attempt to reflect
the assumed similar (but not identical) treatment effect
across trials. Patient-level covariates (as listed above) will
then be incorporated into the model in an attempt to
account for some of the remaining statistical heterogene-
ity. An attempt will be made to incorporate these covari-
ates first of all by assuming their effect to be constant
across all trials and subsequently by assuming some het-
erogeneity in the covariate effect across trials by modelling
them either as fixed or random effects. Finally, treatment-
covariate interactions will be investigated by including
additional variables and adopting a similar approach.
If IPD are not available for some trials, the potential for
bias will be investigated as follows. The reasons for not
being able to obtain the data will be assessed for the
potential for bias. Results using aggregate data from these
trials will be compared with results using aggregate data
from trials where IPD have been supplied, and any differ-
ence investigated. The analysis plan will be reviewed in
light of the availability of IPD but prior to any compara-
tive analyses.
Discussion
Predictive models generated by our analysis should allow
more effective counselling of women at risk of preterm
delivery and thus more cost effective use of cerclage.
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